Articles from Molecular Instruments

Molecular Instruments® (MI), inventor of the HCR™ technology, today announces the launch of HCR™ Pro RNA-ISH for manual workflows, expanding the unmatched performance and versatility of the HCR™ imaging platform by enabling extreme-sensitivity RNA imaging with chromogenic or fluorescent staining in an accessible and flexible format tailored for hands-on research applications.

Molecular Instruments®, Inc. (MI), a company powering the future of bioimaging, today announced a significant advancement in dermatological diagnostics through the successful development and implementation of novel laboratory-developed tests (LDTs) at the Department of Dermatology at Yale School of Medicine. The LDTs, powered by MI’s HCR™ Pro RNA in situ hybridization (RNA-ISH) technology, comprise a unique four-biomarker panel to differentiate between and sub-classify psoriasis and atopic dermatitis (eczema) skin biopsies and guide treatment selection.

Molecular Instruments® (MI), founded by the inventor of the HCR™ technology, today announces the launch of the HCR™ Gold and HCR™ Pro product lines. These offerings significantly expand the HCR™ imaging platform to facilitate academic research and biopharma drug development using either manual or automated workflows. The expanded platform supports fluorescent and chromogenic assays for simultaneous RNA and protein imaging with well-preserved sample morphology.

Leica Biosystems, a cancer diagnostics company and a global leader in workflow solutions, and Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, today announced a partnership to enable fully integrated RNA-ISH using the BOND RX and BOND RXm research staining systems.